Live attenuated vaccines market was valued at $30.2 billion in 2025 and is projected to reach $78.6 billion by 2035, growing at a CAGR of 10.1% during the forecast Period (2026-2035). Government immunization programs and global vaccination campaigns significantly promote the adoption of live attenuated vaccines. Their inclusion in routine immunization schedules for both children and adults ensures steady demand and supports consistent market growth. As a reflection of this structured approach to public health, regulatory authorities in major markets actively evaluate and approve key vaccines to maintain robust immunization coverage.

Methionine market valued at $7,806.5 million in 2025 and is projected to reach $12,743.4 million by 2035, growing at a CAGR of 5.1% during the forecast period (2026-2035). The market encompasses synthetic and bio-based methionine used as an essential amino acid additive across multiple industries, particularly in animal nutrition. Methionine plays a critical role in protein synthesis, metabolism regulation, and growth performance in livestock and poultry, making it one of the most widely used feed additives globally. The market is witnessing sustained expansion supported by increasing global livestock production, rising demand for high-quality animal protein, and continuous innovations in feed additives that improve nutrient absorption and reduce environmental impact. Growth is further supported by advancements in amino acid fermentation technologies, improved feed conversion efficiency requirements, and increasing regulatory emphasis on sustainable livestock production.

Lincomycin hydrochloride market valued at $325.4 million in 2025 and is projected to reach $438.2 million by 2035, growing at a CAGR of 3.1% during the forecast period (2026-2035). The market comprises antibiotic formulations used to treat serious bacterial infections, particularly those caused by gram-positive organisms. The market is witnessing steady global growth driven by the rising incidence of bacterial infections, increasing demand for effective antibiotic therapies, and expanding healthcare access across developing regions. Growth is further supported by the continued use of lincomycin in both human and veterinary medicine, particularly in treating resistant infections and severe cases where alternative antibiotics may be less effective. Pharmaceutical manufacturers are focusing on improving production capabilities, enhancing formulation stability, and ensuring regulatory compliance to maintain consistent supply.

Immune BCG market valued at $450.3 million in 2025 and is projected to reach $735 million by 2035, growing at a CAGR of 5.1% during the forecast period (2026-2035). The market comprises Bacillus Calmette–Guérin (BCG) vaccines and immunotherapies used primarily for tuberculosis prevention and bladder cancer treatment. The market is witnessing steady global growth driven by the continued burden of tuberculosis and the expanding use of BCG in oncology, particularly for non-muscle invasive bladder cancer treatment. Growth is further supported by national immunization programs, increasing awareness regarding early disease prevention, and rising healthcare access in emerging economies. Pharmaceutical manufacturers are focusing on improving production capacity, ensuring supply chain stability, and enhancing formulation quality to address periodic global shortages. 

Hydrolyzed placental protein market valued at $535.3 million in 2025 and is projected to reach $1,158.1 million by 2035, growing at a CAGR of 8.1% during the forecast period (2026-2035). The market comprises bioactive protein extracts derived from animal placentas, processed through hydrolysis to enhance absorption and efficacy. The market is witnessing steady global expansion driven by increasing demand for anti-aging and regenerative skincare solutions, along with rising interest in nutraceutical and therapeutic applications. Growth is further supported by advancements in extraction technologies, improved product standardization, and expanding consumer awareness regarding bioactive ingredients. The cosmetics sector remains the dominant application segment, with hydrolyzed placental protein widely used in serums, creams, and injectable formulations for skin rejuvenation. Additionally, the growing use of these proteins in functional foods and pharmaceuticals for immune support, tissue repair, and hormonal balance is contributing to long-term market growth.

Gout therapeutics market valued at $1,645.2 million in 2025 and is projected to reach $2,683.1 million by 2035, growing at a CAGR of 5.0% during the forecast period (2026-2035). The market includes pharmacological treatments aimed at managing uric acid levels and relieving inflammation associated with gout. The market is experiencing steady global growth driven by the increasing prevalence of hyperuricemia, rising incidence of lifestyle-related disorders, and growing awareness regarding early diagnosis and treatment of gout. Expansion is further supported by aging populations, increasing obesity rates, and dietary patterns associated with high purine intake. Pharmaceutical companies are focusing on developing advanced urate-lowering therapies, combination drugs, and biologics to improve patient outcomes. Additionally, improved access to healthcare services and the availability of generic medications are contributing to wider treatment adoption across emerging economies. 

Liquid cooling QD Coupling market was valued at $743 million in 2025 and is projected to reach $2,147.7 million by 2035, growing at a CAGR of 11.3% during the forecast Period (2026-2035). Universal quick disconnect (UQD) devices are designed for fast, secure, and leak-resistant connection or disconnection of liquid cooling lines, widely used in data centers, automotive, and industrial systems to enhance efficiency and safety. Rising server densities and the growing computational demands of AI workloads are driving the adoption of liquid cooling systems across data centers and high-performance computing environments. This trend has significantly increased the need for reliable quick disconnect couplings, which play a crucial role in enabling efficient thermal management and minimizing operational downtime. To meet these evolving requirements, recent industry developments have introduced advanced coupling solutions.

Ephrin type B receptor market valued at $2,710.5 million in 2025 and is projected to reach $7,848.3 million by 2035, growing at a CAGR of 11.3% during the forecast period (2026-2035). The market comprises targeted therapeutics and investigational agents designed to modulate Ephrin (Eph) receptor signaling pathways, which play a critical role in tumor progression, angiogenesis, and metastasis. The market is witnessing steady growth driven by increasing research focus on targeted cancer therapies, rising incidence of aggressive and treatment-resistant tumors, and growing investment in precision oncology. Expansion is further supported by advancements in receptor tyrosine kinase inhibitors, increasing adoption of biomarker-driven therapies, and the integration of Eph receptor modulation into combination treatment strategies. Pharmaceutical and biotechnology companies are actively progressing clinical pipelines involving EphB receptor inhibitors, particularly for rare and hard-to-treat cancers. Ongoing innovations in molecular targeting, immuno-oncology combinations, and personalized medicine approaches are further strengthening long-term market potential.

E3 ubiquitin protein ligase XIAP market valued at $530.7 million in 2025 and is projected to reach $865.5 million by 2035, growing at a CAGR of 5.0% during the forecast period (2026-2035). The market encompasses targeted therapeutic agents designed to inhibit X-linked inhibitor of apoptosis protein (XIAP), a key regulator of apoptosis in cancer cells. These therapies aim to restore programmed cell death and improve treatment outcomes in resistant tumor types. The market is experiencing steady growth driven by the increasing global burden of cancer, rising focus on targeted and combination therapies, and expanding clinical research in apoptosis modulation. Growth is further supported by advancements in small-molecule inhibitors, increasing number of clinical trials evaluating XIAP inhibitors in combination with chemotherapy and immunotherapy, and growing investments by pharmaceutical and biotechnology companies in oncology drug development. The ability of XIAP inhibitors to overcome treatment resistance and enhance tumor cell sensitivity to existing therapies is a key factor accelerating market adoption.

Liquid cooling components market was valued at $7.8 billion in 2025 and is projected to reach $24.5 billion by 2035, growing at a CAGR of 12.2% during the forecast Period (2026-2035). Increased funding is driving the expansion of manufacturing capabilities for high-performance cooling components such as cold plates, pumps, chillers, and coolant systems, which are essential to meet the rising demand from data centers and high-density computing environments. This trend reflects a broader market focus on scaling production and enhancing regional operations to support the deployment of advanced liquid cooling solutions. For instance, in April 2025, Iceotope Technologies raised $56?million in Series C funding led by bp Ventures and Hostway, including new strategic support from Fujitsu. These funds are being used to scale manufacturing and expand North American operations, particularly through a new facility in Texas focused on precision immersion cooling systems.